drugset / Trial / NCT00741598
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
Phase 4
Completed
72 enrolled
Icahn School of Medicine at Mount Sinai
Massachusetts General Hospital · collabNational Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.
Timeline
- Start
- 2008-09
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 8 mg | — |
| Subject | Galantamine | Small molecule | 24 mg | — |